Retinal Vasculitis Associated with Tislelizumab in a Patient with Esophageal Squamous Cell Carcinoma

To our knowledge, retinal vasculitis associated with tislelizumab has not been previously reported. This case highlights the need for close ophthalmologic monitoring in patients receiving immune checkpoint inhibitors, as ocular immune-related adverse events can develop or recur at any point during treatment and even be asymptomatic.